Sanofi and Regeneron's Praluent closes in on sales-boosting CV nod
admin 12th September 2018 Uncategorised 0Sanofi and Regeneron spent months waiting for cardiovascular outcomes data on their PCSK9 drug Praluent as they watched Amgen tout its rival drug’s CV benefits. But they won’t have to wait much longer to hear the word on their own CV approval.
More: Sanofi and Regeneron's Praluent closes in on sales-boosting CV nod
Source: fierce